Q2 EPS Estimates for Sutro Biopharma Lifted by HC Wainwright

Sutro Biopharma, Inc. (NASDAQ:STRO) – Investment analysts at HC Wainwright upped their Q2 2026 earnings per share (EPS) estimates for shares of Sutro Biopharma in a report issued on Friday, May 15th. HC Wainwright analyst A. Maldonado now expects that the company will post earnings of ($2.33) per share for the quarter, up from their prior estimate of ($2.58). HC Wainwright currently has a “Buy” rating and a $50.00 target price on the stock. The consensus estimate for Sutro Biopharma’s current full-year earnings is ($9.04) per share. HC Wainwright also issued estimates for Sutro Biopharma’s Q3 2026 earnings at ($2.32) EPS, Q4 2026 earnings at ($2.32) EPS, FY2026 earnings at ($9.30) EPS, FY2027 earnings at ($4.92) EPS, FY2028 earnings at ($7.29) EPS, FY2029 earnings at ($5.09) EPS and FY2030 earnings at ($5.23) EPS.

A number of other brokerages have also weighed in on STRO. Wells Fargo & Company raised shares of Sutro Biopharma from an “equal weight” rating to an “overweight” rating and upped their price target for the stock from $8.00 to $27.00 in a research note on Tuesday, March 24th. Lifesci Capital raised shares of Sutro Biopharma to a “strong-buy” rating in a research note on Friday, May 1st. Deutsche Bank Aktiengesellschaft upped their price target on shares of Sutro Biopharma from $51.00 to $55.00 and gave the stock a “buy” rating in a research note on Wednesday, March 25th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Sutro Biopharma in a research note on Friday, May 8th. Finally, Citigroup reaffirmed an “outperform” rating on shares of Sutro Biopharma in a research note on Friday, April 17th. Three equities research analysts have rated the stock with a Strong Buy rating, seven have assigned a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average target price of $48.25.

Sutro Biopharma Trading Down 11.5%

NASDAQ STRO opened at $34.48 on Tuesday. Sutro Biopharma has a 52 week low of $6.74 and a 52 week high of $43.85. The stock has a market cap of $571.33 million, a price-to-earnings ratio of -2.00 and a beta of 1.63. The company has a 50-day moving average price of $29.43 and a two-hundred day moving average price of $18.50.

Sutro Biopharma (NASDAQ:STRO) last announced its quarterly earnings data on Thursday, May 14th. The company reported ($2.94) earnings per share for the quarter, missing analysts’ consensus estimates of ($2.74) by ($0.20). The company had revenue of $14.52 million for the quarter, compared to analyst estimates of $8.89 million.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in STRO. AQR Capital Management LLC increased its stake in Sutro Biopharma by 1,052.8% in the 1st quarter. AQR Capital Management LLC now owns 1,320,917 shares of the company’s stock valued at $859,000 after buying an additional 1,206,330 shares during the period. Orbimed Advisors LLC acquired a new position in shares of Sutro Biopharma during the 1st quarter worth $19,956,000. Jane Street Group LLC acquired a new position in Sutro Biopharma in the 2nd quarter valued at $492,000. ADAR1 Capital Management LLC grew its stake in Sutro Biopharma by 681.8% in the 1st quarter. ADAR1 Capital Management LLC now owns 524,441 shares of the company’s stock valued at $13,064,000 after buying an additional 457,364 shares during the last quarter. Finally, Jacobs Levy Equity Management Inc. acquired a new position in Sutro Biopharma in the 3rd quarter valued at $387,000. Institutional investors and hedge funds own 96.99% of the company’s stock.

About Sutro Biopharma

Sutro Biopharma, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of novel biologic drug candidates in the fields of oncology and immunology. The company leverages a proprietary cell-free protein synthesis platform, XpressCF™, to design and produce complex, multi-specific proteins that include antibody-drug conjugates, bispecific antibodies, and cytokine fusion proteins. This platform enables rapid generation and optimization of protein therapeutics that may not be feasible with traditional cell-based expression systems.

Founded in 2003 and headquartered in South San Francisco, California, Sutro Biopharma has built a pipeline of immuno-oncology candidates in various stages of preclinical and clinical development.